GILD  Gilead Sciences Inc.

Exchange

NASDAQ

Sector

Health Care

Industry

Biotechnology: Biological Products (No Diagnostic Substances)

Market Cap.

141.9B

Vuru Grade

75.00/100

Current Price

$94.08
-14.37 (-13.25%)

Growth Price

$26.98
Overvalued by 71.33%

Stability Price

$15.14
Overvalued by 83.90%

Company Metrics

  • 19.32 P/E
  • 7.91 P/S
  • 12.08 P/B
  • 5.613 EPS
  • 39.33% Cash ROIC
  • 0.34 Cash Ratio
  • 0 / 0% Dividend
  • 14.99M Avg. Vol.
  • 1.69B Shares
  • 141.9B Market Cap.

Company Description

Gilead Sciences, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for the treatment of life threatening diseases worldwide. Its products include Atripla, Truvada, Viread, Emtriva for the treatment of human immunodeficiency virus infection in adults; Hepsera, an oral formulation for the treatment of chronic hepatitis B; AmBisome, a amph...
more


Download 10 Years of Financial Statements:
Income Statement   Balance Sheet   Cash Flow

News

Could Gilead Sciences, Inc. Be a Top Stock in 2015?
Motley Fool - 15 hours ago
Despite last weeks' oil-induced swoon, the S&P 500 is still up by 8% for the year. But don't bother bragging about this to Gilead Sciences (NASDAQ: GILD ) shareholders -- through the weekend, Gilead shares had nearly quintupled the broader market's ...
Commentary On Gilead Sciences' Recent Plunge - Seeking Alpha
Gilead Sciences (GILD) Should Be Worried: Achillion Pharmaceuticals' (ACHN ... - Bidness ETC
Why Ocwen Financial, Gilead Sciences and United States Steel Are 3 of Today's ...
Investorplace.com - 6 hours ago
Gilead185 Why Ocwen Financial, Gilead Sciences and United States Steel Are 3 of Todays Worst Gilead Sciences is out, AbbVie Inc. (ABBV) is in, and anyone who was holding GILD stock as of this morning paid the price for it. Gilead Sciences closed down ...
Mid-Day Losers From December 22: Gilead, Ocwen Financial And More - Benzinga
Gilead Sciences, Inc. Gets Some Competition (but Not Really)
Motley Fool - Dec 21, 2014
AbbVie (NYSE: ABBV ) gained Food and Drug Administration approval for its new hepatitis C cocktail, dubbed Viekira Pak, on Friday, and priced the regimen at $83,319 for the 12-week regimen.
Gilead Sciences (GILD) Signs Deal With Ono Pharmaceutical For Exclusive ...
Bidness ETC - 15 hours ago
Gilead Sciences, Inc. (NASDAQ:GILD) announced Friday it has entered into an agreement with Osaka, Japan-based Ono Pharmaceutical Co.
Benzinga's Top #PreMarket Losers - Benzinga
Gilead Sciences Inc. (NASDAQ:GILD) Listed As a Pre Loser- Halozyme ... - StreetWise Report
Bank Of America Downgrades Gilead Sciences, Sees Possible Pricing War
Benzinga - 8 hours ago
Bank of America downgraded Gilead Sciences, Inc. (NASDAQ: GILD) Monday from Buy to Underperform and cut its price target from $130 to $87.
Which Biotech Will Become the Next Gilead Sciences, Inc.?
Motley Fool - Dec 16, 2014
When it comes to investing in the biotech sector, perhaps no company has been a better poster child for success than Gilead Sciences (NASDAQ: GILD ) . Over the trailing three years Gilead shares have rocketed higher by better than 400% as existing ...
Examining Gilead Sciences' Future Pipeline - Seeking Alpha
Traders Buy Gilead Sciences on Weakness (GILD) - The Legacy
Express Scripts (ESRX) Sides With AbbVie (ABBV), Abandons Gilead Sciences ...
Bidness ETC - 16 hours ago
Express Scripts further said that beginning January 1, 2015, it will exclude drugs by Gilead Sciences, Inc. (NASDAQ:GILD) and Johnson & Johnson (NYSE:JNJ) for the same indication from its plan, further fuelling the ongoing price war over new hepatitis ...
Gilead Sciences Inc. (GILD) Is Sinking After Express Scripts Announcement
RTT News - 13 hours ago
Express Scripts (ESRX: Quote) announced Monday that it has negotiated to receive a discount from AbbVie on its Viekira Pak, a treatment for hepatitis C that just received approved from the FDA on Friday.
Express Scripts picks AbbVie over Gilead for hepatitis C drug
MarketWatch - 15 hours ago
Express Scripts Holding Co. ESRX, +1.69% will make an AbbVie Inc. ABBV, -1.09% drug the exclusive option for patients with the most common form of hepatitis C. The move will help the drug maker take market share from Gilead Sciences Inc. GILD, -14.34% ...
Why I Am Not Selling Gilead
Seeking Alpha - 7 hours ago
AbbVie's (NYSE:ABBV) hepatitis C treatment was approved by the FDA last Friday and as expected, the company did not significantly undercut the price of Gilead's (NASDAQ:GILD) Harvoni. The treatment cost of AbbVie's Viekira Pak is $83,319. This is ...